Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK)

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

March 23, 2018

Primary Completion Date

December 28, 2021

Study Completion Date

December 31, 2021

Conditions
Major Depressive Disorder
Interventions
DRUG

F-18 AV-45

In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.

DRUG

F-18-THK-5351

In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. All subjects will further undergo F-18-THK-5351 image study to detect underlying tau pathology. By doing this, the investigators will elucidate the neurodegenerative pathophysiology behind the link between depressive disorder and the subsequent development of dementia.

Trial Locations (1)

333

Chang Gung Memorial Hospital, Taoyuan District

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT03430869 - Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK) | Biotech Hunter | Biotech Hunter